argenx (ARGX) Stock Forecast & Price Target

Argenx has demonstrated significant growth in its financial performance, with revenues reaching $790 million in Q1 2025, representing a 98% year-over-year increase, and $949 million in Q2 2025, marking a 97% year-over-year rise. The accelerated adoption of the pre-filled syringe format and the expansion of its treatment indications, particularly in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), are key contributors to this positive trajectory. Furthermore, the company is well-positioned for continued growth, with ongoing opportunities for expansion in various therapeutic areas and increasing prescriber engagement, reflecting a robust outlook for future earnings.

Argenx's financial outlook appears negative due to the potential for delays or failures in obtaining regulatory approvals for its drug candidates, which could adversely affect the company's share price. Furthermore, the company's primary product, Vyvgart, may struggle to achieve significant market penetration, with indications that only 24% of the target patient population may be reached by the end of 2025, raising concerns over revenue generation. Additionally, the competitive landscape in the autoimmune and oncologic disease sectors presents a significant challenge, as both established companies and emerging players are actively developing similar therapies, potentially limiting Argenx's market share and growth prospects.